Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma
2025
Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF-Mutant Melanoma
Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF-Mutant Melanoma
Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma
Frontline Immunotherapy Treatment Options in Advanced or Metastatic Cutaneous Melanoma
Moles can become melanomas through nongenetic transitions, UC Irvine study shows
Moles can become melanomas through nongenetic transitions, UC Irvine study shows